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Summary Expression of alpha-l-antitrypsin (AAT) in tumour cells of 102 surgically resected lung adenocar-
cinomas was examined by immunohistochemical method using anti-AAT antiserum. While only 13 cases
(13%) were negative for AAT expression, 89 cases (87%) contained AAT at varying degrees. The degree of
AAT-positive tumour cells was significantly higher in advanced cases than in early cases. Clinical follow-up
study of the patients, particularly in stage I, showed that strongly AAT-positive cases have poor prognosis
than weak-to-moderately AAT-positive or AAT-negative cases. Thus, AAT expression status in tumour cells
of lung adenocarcinoma may be a biological marker of prognostic significance in regard to tumour growth.
Alpha-1-antitrypsin (AAT) is a glycoprotein produced by
liver cells and secreted into the serum (Laurell & Jeppsson,
1975). Since AAT can inactivate a wide variety of proteolytic
enzymes such as pancreatic and leukocyte elastase, trypsin,
chymotrypsin, collagenase, plasmin and thrombin, it is con-
sidered to be important in regulating a variety of proteolytic
and thromboplastic processes on both systemic and local
levels (Rimon et al., 1966; Eisen et al., 1970; Koj et al., 1972;
Beatty et al., 1980). AAT is expressed not only in normal
livers but also in other normal tissues such as the lung, gall
bladder, pancreas, and the gastrointestinal tract (Tuttle &
Jones, 1975; Ray et al., 1978; Kittas et al., 1982a; Geboes et
al., 1982; Tahara et al., 1984; Aroni et al., 1984). Moreover,
AAT has also been demonstrated in several neoplasms in-
cluding carcinomas, mesenchymal tumours, hemopoietic and
brain tumours (Reintoft & Hargerstrand, 1979; Kittas et al.,
1982b; Glasgow et al., 1982; Aroni et al., 1984; Tahara et al.,
1984; Krugliak et al., 1986; Wittekind et al., 1986; Sawaya et
al., 1987; Soini & Miettinen, 1989; Kataoka et al., 1989;
Perlmutter et al., 1989; Karashima et al., 1990). The presence
of AAT in tumour cells is now considered to be due to its
production by tumour cells themselves (Glasgow et al., 1982;
Perlmutter et al., 1989; Kataoka et al., 1989). However, its
significance in neoplastic tissues remains unknown.
Recently, with few exceptions, several reports have shown
that cases with AAT expression in tumour cells had worse
prognosis than those without AAT expression, suggesting
that AAT production in tumours cells may correlate with
more aggressive behaviour in some gastrointestinal cancers
(Tahara et al., 1984; Wittekind et al., 1986; Karashima et al.,
1990).
AAT expression in lung cancer has not been studied yet.
Therefore, in order to clarify the clinicopathological
significance of AAT expression in lung cancer, the authors
performed a preliminary immunohistochemical study of its
incidence in lung adenocarcinoma.
Materials and methods
Formalin-fixed and paraffin-embedded tissue blocks from 102
surgically resected specimens of primary adenocarcinoma of
the lung were studied. All patients underwent curative oper-
ation. The patients comprised 63 men and 39 women, with
ages ranging from 19 to 79 years (mean 60.9). According to
the international TNM staging system (Mountain, 1986),
these cases comprised 51 patients in pathological stage I
(p-stage I), 12 in pathological stage II (p-stage II), 38 in stage
IIIA (p-stage IIIA), and one in pathological stage IIIB (p-
stage IIIB).
Immunohistochemistry was performed according to a
modified method of Hsu et al. (1981). Briefly, sections (4 tim
thick) were deparaffinised, and endogenous peroxidase activ-
ity was blocked using 0.3% hydrogen peroxide in methanol.
After immersion in 2% normal goat serum, the sections were
incubated with specific rabbit antisera overnight at 4'C, and
subsequently with biotinylated goat-rabbit IgG (Vector) and
avidin-biotin peroxidase complex (Vectastain ABC kit, Vec-
tor) for 30min each at room temperature. The peroxidase
reaction used 0.02% 3,3'-diaminobenzidine tetrahydrochlor-
ide in 0.05 M TRIS buffer, pH 7.6, containing 0.01% hydro-
gen peroxide. Sections were counterstained with Mayer's
haematoxylin. In all specimens, serum in blood vessels or
some macrophages was used as an internal positive control
for AAT immunoperoxidase staining, while normal rabbit
serum was used for negative controls. Anti-AAT antiserum
purchased from Dakopatts, Denmark, was used at a dilution
of 1:300. Specificity of the antiserum was confirmed as des-
cribed by Tahara et al. (1984) and Karashima et al. (1990).
Staining results were evaluated semi-quantitatively, taking
into account the percentage of AAT-positive tumour cells
within tumour tissues [<1% = negative (-), 1-80% =
weak-to-moderately positive ( + ), 80% < = strongly positive
(+ +)]. The Kaplan-Meier method was used to calculate
postoperative survival rate, and prognostic significance was
evaluated by the generalised Wilcoxon test. The chi-square
test was used for further statistical analysis. P<0.05 was
considered to be significantly different.
Results
Eighty-nine cases (87%) of primary adenocarcinoma express-
ed AAT in tumour cells, admixed with AAT-positive and
-negative tumour cells in varying degrees within the tumour
tissues (Figure 1, Table I). Only 13 patients (13%) were
negative for AAT expression in tumour cells. Table I shows
the relationship between AAT immunoreactivity in tumour
cells and clinical status. The degree of AAT-positive tumour
cells was significantly higher in advanced p-stage II, IIIA and
IIIB cases than that in early p-stage I cases (P<0.01). While
there was no correlation between AAT immunoreactivity and
p-T factor, cases with nodal involvement were more strongly
positive than those without nodal involvement (P<0.05).
Postoperative survival curves among the three patients
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Figure 1 AAT expression in lung adenocarcinoma (original
magnification, x 40). a, A mild-to-moderately AAT-positive case
showing an admixture of AAT-positive (arrow) and AAT-nega-
tive tumour cells. b, A strongly AAT-positive case showing strong
immunoreactivity for AAT in almost all tumour cells.
Table I Correlation between AAT expression in tumour cells and
clinical status
AATexpression (%)
No. (-) (+) (+ +)
P-Stage
I 51 11 (22) 32 (63) 8 (15)
II 12 0 (0) 8 (67) 4 (33)
IIIA 38 2 (5) 22 (58) 14 (37)
III B 1 0 (0) 1 (100) 0 (0)
II+IIIA+IIIB 51 2 (4) 31 (61) 18 (35)
p-T factor
TI 49 5 (10) 30 (61) 14 (29)
T2, 3 53 8 (15) 33 (62) 12 (23)
p-N factor
NO 54 11 (20) 34 (63) 9 (17)
N1, 2, 3 48 2 (4) 29 (60) 17 (36)
Total 102 13 (13) 63 (62) 26 (25)
P<0.01: stage I vs stage II + III A + III B. P<0.05: NO vsNl, 2, 3.
group, AAT negative, weak-to-moderately AAT-positive and
strongly AAT-positive cases are shown in Figure 2a. Average
5-year survival rates were 70% in AAT-negative cases, 61%
in weak-to-moderately AAT-positive cases and 40% in
strongly AAT-positive cases. Patients in this last group had
slightly shorter survival times that AAT-negative or weak-to-
moderately AAT-positive cases, but this was not statistically
significant. In 51 cases at stage I (Figure 2b), average 5-year
survival rates were 75% in AAT-negative cases, 74% in
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Figure 2a Survival curves of all cases with lung adenocarcinoma
according to the extent of AAT expression. * AAT (-) n = 13;
O AAT (+ ) n = 63; E) AAT ( + +) n = 26. b, Survival curves
of the patients with p-stage I lung adenocarcinoma according to
the extent of AAT expression. The generalised Wilcoxon test
shows that the difference is statistically significant between
strongly AAT-positives and AAT-negatives (P<0.05), and
between strongly AAT-positives and mild-to-moderately positives
(P<0.01). * AAT (-) n= 11; 0 AAT (+) n=32; (0 AAT
(++) n=8.
weak-to-moderately AAT-positive cases and 35% in strongly
AAT-positive cases. According to the generalised Wilcoxon
test, statistical differences were observed between strongly
AAT-positives and AAT-negatives (P<0.05), and between
strongly AAT-positives and weak-to-moderately AAT-posi-
tives (P<0.01).
Discussion
AAT expression in tumour cells of the digestive system has
been immunohistochemically studied (Reintoft & Hager-
strand, 1979; Kittas et al., 1982b; Tahara et al., 1984; Aroni
et al., 1984; Wittekind et al., 1986; Karashima et al., 1990).
In colorectal cancer, Karashima et al. (1990) reported that
the incidence of AAT expression was markedly higher in
advanced cases than in early cases, and that AAT-positive
cases had a poor prognosis than AAT-negative cases, partic-
ularly in early stages. Tahara et al. (1984) reported similar
findings in gastric cancer. Our results showed that AAT
expression in tumour cells of lung adenocarcinoma is also
strongly associated with tumour growth and prognosis. How-
ever, according to the balance between proteolytic and its
inhibitory activities in tumour cells, these results are appar-
ently inconsistent with previous reports that high activity of
proteolytic enzymes, e.g. serine proteases, in tumour cells is
associated with malignant potency (Mignatti et al., 1986;
Tryggvason et al., 1987; Zucker, 1988).
To explain this discrepancy, the following possibilities are
presented. First, AAT may have a function of modulating
host-immunodefence mechanisms in favour of tumours cells;
it may suppress the blastogenic or cytotoxic reactions of
lymphocytes by inhibiting T cell-mediated cytotoxicity, anti-
body-dependent cell-mediated cytotoxicity and natural killer-
cell activity (Arora et al., 1978; Redelman & Hudig, 1980;
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Ades et al., 1982). Sawaya et al. (1987) suggested that AAT
produced in brain tumours may protect against inflammatory
activity of the host. Therefore, AAT in tumour cells may
have the capacity to promote tumour development and
metastasis by incapacitating host anti-tumour defense mech-
anisms. Secondly, McKeehan et al. (1986) found that AAT
may exhibit growth-stimulating activities on endothelial cells,
maintaining blood circulation within tumour tissues for
tumour development. Thirdly, AAT may act as a proteolytic
enzyme 'carrier' rather than as an 'inhibitor' (Beatty et al.,
1982). Karashima et al. (1990) speculated that the protease-
AAT complex may dissociate in the presence of suitable
substrate and degrade extracellular matrices by releasing pro-
teolytic protease.
In conclusion, although further study will be required to
elucidate the mechanism and role of AAT expression in lung
adenocarcinoma, we confirmed that strongly AAT-positive
lung adenocarcinomas was characterised by its high malig-
nancy and poor prognosis. Our results indicate that AAT
expression may be a biological marker of potential prognos-
tic significance, particularly in early cases of lung adenocar-
cinoma.
The authors are grateful to Yumiko Koyanagi and Hiroko Funai for
their technical assistance.
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